Shangzhen Zhou

发表

Transgene Expression Transfer : Role of Cellular FKBP 52 Protein in Adeno-Associated Virus Type 2-Mediated Gene

Arun Srivastava, J. Hansen, A. Srivastava, 2001 .

Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs

M. Haskins, K. High, V. Arruda, 2016, PloS one.

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery

J. F. Wright, Shangzhen Zhou, H. Spencer, 2013, Molecular therapy. Methods & clinical development.

Mutations on the External Surfaces of Adeno-AssociatedVirus Type 2 Capsids That Affect Transduction andNeutralization

Shangzhen Zhou, P. Colosi, R. Surosky, 2006, Journal of Virology.

Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography.

J. F. Wright, J. F. Wright, J. Sommer, 2007, Journal of virological methods.

Specific adeno‐associated virus serotypes facilitate efficient gene transfer into human and non‐human primate mesenchymal stromal cells

J. Rasko, J. F. Wright, Shangzhen Zhou, 2007, The journal of gene medicine.

High-throughput screening and biophysical interrogation of hepatotropic AAV.

K. High, Shangzhen Zhou, Anand S. Bhagwat, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.

Theresa A. Storm, M. Kay, D. Grimm, 2003, Blood.

Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys

J. F. Wright, X. Anguela, K. High, 2013, Science Translational Medicine.

Robust ZFN-mediated genome editing in adult hemophilic mice.

Y. Doyon, Jeffrey C. Miller, P. Gregory, 2013, Blood.

AKT3 Gene Transfer Promotes Anabolic Reprogramming and Photoreceptor Neuroprotection in a Pre-clinical Model of Retinitis Pigmentosa.

J. Bennett, Shangzhen Zhou, Tyler E Papp, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.

V. Arruda, Shangzhen Zhou, F. Mingozzi, 2015, Blood.

Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B

B. Byrne, R. Herzog, Shangzhen Zhou, 2011, Front. Microbio..

Safe, Long-term Hepatic Expression of Anti-HCV shRNA in a Nonhuman Primate Model

A. Burdick, A. Kolykhalov, J. F. Wright, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.

V. Haurigot, H. Stedman, J. F. Wright, 2010, Blood.

Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs

V. Haurigot, H. Stedman, J. F. Wright, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B

C. Dunbar, R. Donahue, M. Metzger, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.

J. F. Wright, K. High, V. Arruda, 2007, Blood.

Prophylactic immune tolerance induced by changing the ratio of antigen‐specific effector to regulatory T cells

M. Atkinson, R. Herzog, Shangzhen Zhou, 2009, Journal of thrombosis and haemostasis : JTH.

Characterization of Wild-Type Adeno-Associated Virus Type 2-Like Particles Generated during Recombinant Viral Vector Production and Strategies for Their Elimination

Arun Srivastava, S. Ponnazhagan, D. Kube, 1998, Journal of Virology.

AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura.

J. F. Wright, Shangzhen Zhou, X. Zheng, 2013, Blood.

CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.

H. Ertl, S. Faust, K. High, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes

D. Scott, A. D. De Groot, V. Haurigot, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.

H. Ertl, R. Herzog, A. Srivastava, 2013, Blood.

Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.

J. F. Wright, Shangzhen Zhou, K. Bankiewicz, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

variant administration of rAAV vector encoding a novel human factor VIII Therapeutic levels of FVIII following a single peripheral vein

P. Fagone, A. Nienhuis, O. Christophe, 2014 .

Successful Replication ofParvovirus B19intheHuman Megakaryocytic Leukemia CellLineMB-02

A. Srivastava, Shangzhen Zhou, 1993 .

Comparative AAV-eGFP Transgene Expression Using Vector Serotypes 1–9, 7m8, and 8b in Human Pluripotent Stem Cells, RPEs, and Human and Rat Cortical Neurons

Thu T. Duong, J. Bennett, Jieyan Pan, 2019, Stem cells international.

Successful treatment of canine hemophilia by continuous expression of canine FVIIa.

U. Giger, P. Margaritis, T. Nichols, 2009, Blood.

Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.

M. Poncz, V. Arruda, Shangzhen Zhou, 2013, Blood.

Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.

L. Couto, C. Scallan, Shangzhen Zhou, 2006, Blood.

In vivo genome editing restores hemostasis in a mouse model of hemophilia

Hojun Li, Frederic D. Bushman, Katherine A. High, 2011, Nature.

Unexpected Role of PACE/Furin Cleavage Site in FVIII Biology: Implications for Hemophilia a Therapy

T. Nichols, V. Arruda, Shangzhen Zhou, 2014 .

Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.

H. Kazazian, M. Ozelo, T. Nichols, 2010, Blood.

Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.

H. Kazazian, R. Sarkar, T. Nichols, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII.

P. Margaritis, D. Bellinger, T. Nichols, 2016, Blood.

GENE THERAPY Sustained correction of FVII de ﬁ ciency in dogs using AAV-mediated expression of zymogen FVII

P. Margaritis, D. Bellinger, T. Nichols, 2016 .

In vivo genome editing of the albumin locus as a platform for protein replacement therapy.

Y. Doyon, Jeffrey C. Miller, David E. Paschon, 2015, Blood.

Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.

P. Margaritis, K. High, Shangzhen Zhou, 2011, Blood.

Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B.

H. Ertl, R. Herzog, K. High, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Multi-year Therapeutic Benefit of AAV Serotypes 2, 6 and 8 Delivering Factor VIII to Hemophilia A Mice and Dogs Running Title: Long Term Liver-specific AAV-FVIII Therapy in Dogs

Morag, L. Couto, C. Scallan, 2006 .

Inhibition of hepatitis C virus replication using adeno‐associated virus vector delivery of an exogenous anti–hepatitis C virus microrna cluster

V. Haurigot, L. Couto, Shangzhen Zhou, 2010, Hepatology.

Amelioration of Neurosensory Structure and Function in Animal and Cellular Models of a Congenital Blindness.

T. Aleman, G. Ying, A. D. den Hollander, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Adeno-associated Virus 2-Mediated Transduction and Erythroid Lineage-Restricted Long-Term Expression of the Human β-Globin Gene in Hematopoietic Cells from Homozygous β-Thalassemic Mice

A. Srivastava, K. Qing, M. Yoder, 2001 .

Treatment of Diabetes and Long-Term Survival After Insulin and Glucokinase Gene Therapy

C. Mann, E. Ayuso, V. Haurigot, 2013, Diabetes.

Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.

J. Sommer, K. High, L. Couto, 2006, Blood.

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

J. Sommer, L. Couto, C. Scallan, 2006, Blood.

Effects of transient immunosuppression on adeno associated virus- mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy Running Title: Immunosuppression in AAV8-hFIX treated macaques

J. Sommer, K. High, L. Couto, 2006 .

Novel Caprine Adeno-Associated Virus (AAV) Capsid (AAV-Go.1) Is Closely Related to the Primate AAV-5 and Has Unique Tropism and Neutralization Properties

C. Scallan, Shangzhen Zhou, P. Colosi, 2005, Journal of Virology.

GENE THERAPY Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-speci fi c CD 8 1 T cells

H. Ertl, R. Herzog, A. Srivastava, 2013 .

Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.

K. High, Shangzhen Zhou, F. Mingozzi, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.

J. Orange, K. High, Shangzhen Zhou, 2009, The Journal of clinical investigation.

Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.

R. Sarkar, Jinhui Wang, W. Xiao, 2008, Human gene therapy.

Prolonged Susceptibility to Antibody-mediated Neutralization for Adeno-associated Vectors Targeted to the Liver.

K. High, Shangzhen Zhou, A. Schlachterman, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

T Cell Predominant Response to AAV-Spike Protects hACE2 Mice from SARS-CoV-2 Pneumonia

J. Bennett, H. Stedman, Shangzhen Zhou, 2021, bioRxiv.

418. Adaptation of the Wave Bioreactor to Baculoviral Production of AAV Vectors: Scale-Up Considerations

Shangzhen Zhou, P. Colosi, Glenn P. Pierce, 2004 .

AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models

Aaron D. Black, J. Bennett, L. Sullivan, 2013, PloS one.

Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats.

T. Clackson, L. Berk, V. Rivera, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2

Keyun Qing, Arun Srivastava, J. Hansen, 1999, Nature Medicine.

Axonal transport of adeno-associated viral vectors is serotype-dependent

Gabriele Mittermeyer, Krystof S. Bankiewicz, Shangzhen Zhou, 2012, Gene Therapy.

Adeno-Associated Virus Type 2-Mediated Gene Transfer: Correlation of Tyrosine Phosphorylation of the Cellular Single-Stranded D Sequence-Binding Protein with Transgene Expression in Human Cells In Vitro and Murine Tissues In Vivo

S. Ponnazhagan, D. Kube, V. Dwarki, 1998, Journal of Virology.

Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models

Xiangping Lu, K. Propert, P. Nghiem, 2019, Nature Medicine.

Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver.

K. High, Shangzhen Zhou, A. Schlachterman, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer.

J. F. Wright, G. Acland, C. Zeiss, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety of Same-Eye Subretinal Sequential Readministration of AAV2-hRPE65v2 in Non-human Primates

T. Aleman, J. Bennett, Shangzhen Zhou, 2019, Molecular therapy. Methods & clinical development.

CRISPR Activation Enhances In Vitro Potency of AAV Vectors Driven by Tissue-Specific Promoters

J. Bennett, Shangzhen Zhou, J. Mills, 2019, Molecular therapy. Methods & clinical development.

Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates

John E. Murphy, J. Escobedo, Shangzhen Zhou, 1998, Gene Therapy.

Parvovirus B 19 promoter at map unit 6 confers autonomous replication competence and erythroid specificity to adeno-associated virus 2 in primary human hematopoietic progenitor cells ( viral vectors / tissue-specific expression / hemoglobinopathies / gene therapy )

Xu-Shan Wang, Shangzhen Zhou, A. Srivastava, 2022 .

Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.

J. Escobedo, Shangzhen Zhou, W. Manning, 1998, Human gene therapy.

Induction of Immune Tolerance to Canine FVIII in Hemophilia a Dogs with Inhibitors Using AAV-Mediated Expression of Canine FVIII

H. Kazazian, M. Ozelo, T. Nichols, 2008 .

Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo

R. Hajjar, Shangzhen Zhou, P. Colosi, 2007, Gene Therapy.

High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency

J Montane, E. Ayuso, V. Haurigot, 2010, Gene Therapy.

In vivo genome editing restores hemostasis in a mouse model of hemophilia

F. Bushman, Y. Doyon, David E. Paschon, 2011, Nature.

Robust ZFN-mediated genome editing in adult hemophilic mice.

Y. Doyon, Jeffrey C. Miller, P. Gregory, 2013, Blood.

Modulation of CD8 Modulation of CD8 ++ T cell responses to AAV vectors with IgG- T cell responses to AAV vectors with IgG-derived MHC class II epitopes derived MHC class II epitopes

V. Haurigot, Shangzhen Zhou, F. Mingozzi, 2022 .

Suppression of CTL Responses against AAV-Capsid Epitopes by Peptide-Induced Regulatory T Cells.

K. High, Shangzhen Zhou, F. Mingozzi, 2009 .

Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D

C. Walker, J. Escobedo, Shangzhen Zhou, 1997, Journal of virology.

Prolonged Susceptibility to Antibody-mediated Neutralization for Adeno-associated Vectors Targeted to the Liver.

K. High, Shangzhen Zhou, A. Schlachterman, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura.

Shangzhen Zhou, J. Xiao, Sheng-Yu Jin, 2013, Blood.

In vivo genome editing restores hemostasis in a mouse model of hemophilia

Y. Doyon, David E. Paschon, E. Rebar, 2016 .

Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII.

P. Margaritis, D. Bellinger, T. Nichols, 2016, Blood.

Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue

P. Tak, K. High, Shangzhen Zhou, 2012, Gene Therapy.

Prophylactic immune tolerance induced by changing the ratio of antigen‐specific effector to regulatory T cells

R. Herzog, Shangzhen Zhou, O. Cao, 2009, Journal of thrombosis and haemostasis : JTH.